title: [Therapeutic effect of vildagliptin and insulin aspart injection in elderly patients with type 2 diabetes].
abstract: OBJECTIVE
  To observe the therapeutic effect and safety of vildagliptin combined with insulin aspart injection in elderly patients with type 2 diabetes.
  
  
  METHODS
  Sixty-six elderly patients with type 2 diabetes who had poor blood glucose control with insulin aspart injection were divided into two groups to have additional Vildagliptin (50 mg, twice daily, n=36, observation group) or Acarbose (50 mg, three times a day, n=30, control group). Blood glucose (including FBG and 2hPG), HbA1C, fasting c-peptide, postprandial c-peptide, BMI and GFR were observed after 12 weeks.
  
  
  RESULTS
  In the observation group, FBG, 2hPG and HbA1C decreased significantly (P<0.05), fasting and postprandial c-peptide increased (P<0.05), and BMI and GFR showed no obvious changes (P>0.05). In the control group, 2hPG and HbA1C were significant lowered (P<0.05) but FBG, fasting and postprandial c-peptide, BMI or GFR showed no changes (P>0.05). Compared with those in the control group, FBG in the observation group showed a significant reduction (P<0.05), but no significant differences were found in 2hPG, HbA1C, BMI or GFR (P>0.05). No hypoglycemia occurred in the two groups during the treatment.
  
  
  CONCLUSIONS
  Vildagliptin with insulin aapart injection has equivalent effect with Acarbose combined with insulin aspart injection in decreasing 2hPG and HbA1C without increasing the body weight or the risk to hypoglycemia or causing lowered GFR. Vildagliptin has better effect in decreasing FBG and improving the function of the islet cells.
authors.affiliation: Second Division of Department of Endocrinology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou 510080, China.E-mail: xuling0115@126.com.
authors.forename: Ling
authors.initials: L
authors.lastname: Xu
authors.forename: Kai
authors.initials: K
authors.lastname: Lin
authors.forename: Haiou
authors.initials: H
authors.lastname: Deng
authors.forename: Yinglan
authors.initials: Y
authors.lastname: Li
authors.forename: Ximei
authors.initials: X
authors.lastname: Zhi
authors.forename: Weijie
authors.initials: W
authors.lastname: Zhang
authors.forename: Wen
authors.initials: W
authors.lastname: Wu
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000368:Aged; D001786:Blood Glucose; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007267:Injections; D061267:Insulin Aspart / Q000627:therapeutic use*; D009570:Nitriles / Q000627:therapeutic use*; D011759:Pyrrolidines / Q000627:therapeutic use*; D000077597:Vildagliptin
chemical_list: D000218:Adamantane; D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D061267:Insulin Aspart; D009570:Nitriles; D011759:Pyrrolidines; D000077597:Vildagliptin